SAB Biotherapeutics, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Samuel J. Reich
- Full Time Employees
- 86
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 777 W 41st St. Miami Beach FL United States of America 33140
- IPO Date
- Feb 9, 2021
- CIK
- 0001833214
- Website
- sab.bio
- Similar Companies
- Business
- SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical entity engaged in advancing immunotherapies that leverage fully human antibodies. The firm has harnessed sophisticated genetic engineering and antibody science to cultivate transchromosomic bovine herds capable of generating comprehensive human antibodies tailored to specific diseases, encompassing infectious conditions like severe influenza, as well as immune and autoimmune disorders such as type 1 diabetes. Utilizing its proprietary DiversitAb platform, the company efficiently produces high-potency, fully-human polyclonal antibodies without reliance on human donors, enabling rapid and scalable manufacturing. Its principal investigational asset, SAB-142, a fully-human anti-thymocyte immunoglobulin, is currently undergoing a registrational Phase 2b SAFEGUARD clinical trial for individuals with new-onset Stage 3 type 1 diabetes, with the first patient expected to be dosed by the end of 2025. Additionally, SAB-176, a multi-target biologic for treating or preventing severe influenza, has been granted both Breakthrough Therapy and Fast Track Designations by the FDA. The company also has programs targeting other areas, including earlier-stage candidates for antibiotic resistance and oncology, and previously completed a Phase 3 trial for SAB-185 against COVID-19. Established in 2014, the organization operates from its headquarters in Sioux Falls, South Dakota.
Company News
SAB BIO to Participate in Chardan 10th Annual Healthcare Conference
SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock Rated “Moderate Buy” by Sell-Side Analysts
SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes
SAB Biotherapeutics, Inc. (SABS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
SAB BIO to Participate in Upcoming Investor Conferences
375,000 Shares in SAB Biotherapeutics, Inc. $SABS Purchased by AWM Investment Company Inc.
SAB Biotherapeutics Q2 Earnings Call Highlights
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes
SAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
SAB Biotherapeutics Q1 Earnings Call Highlights
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET
SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026
SAB Biotherapeutics Looks Undervalued If SAB-142 Delivers In Type 1 Diabetes
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants